Tumor-infiltrating lymphocytes have formed the basis of exciting developments in cancer cell and gene therapy research.

TILs changing cancer cell and gene therapy.

Jan 28, 2026 | David Statman

The study of the tumor-infiltrating lymphocyte, or TIL, is moving the field of cell and gene therapy in bold new ways. 

Stay connected.

ACGT delivers two monthly newsletters straight to your email inbox, highlighting ACGT events, funding opportunities, achievements and the latest progress in the development of cancer cell and gene therapies.

The ACGT Monthly E-Newsletter keeps you updated on what we are doing to advance the goal of a cancer-free future, while our Research Roundup is the go-to source for scientific progress in the field, grant opportunities, and publications by our Research Fellows.

Subscribe today to ensure you are part of Alliance for Cancer Gene Therapy.

ACGT Blog

Recent Press Releases